Technical Analysis for OKYO - OKYO Pharma Limited

Grade Last Price % Change Price Change
D 1.47 -2.00% -0.03
OKYO closed up 4.17 percent on Wednesday, March 27, 2024, on 21 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -2.00%
Crossed Above 50 DMA Bullish -2.00%
Calm After Storm Range Contraction -2.00%
NR7 Range Contraction -2.00%
Narrow Range Bar Range Contraction -2.00%
20 DMA Resistance Bearish 2.08%
Spinning Top Other 2.08%
Calm After Storm Range Contraction 2.08%
Down 3 Days in a Row Weakness 2.08%
Down 4 Days in a Row Weakness 2.08%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 3 hours ago
50 DMA Support about 3 hours ago
Down 3% about 3 hours ago
Outside Day about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Uveitis Inflammatory Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease

Is OKYO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.245
52 Week Low 0.9201
Average Volume 203,662
200-Day Moving Average 1.63
50-Day Moving Average 1.49
20-Day Moving Average 1.47
10-Day Moving Average 1.53
Average True Range 0.14
RSI (14) 50.25
ADX 18.05
+DI 24.73
-DI 21.15
Chandelier Exit (Long, 3 ATRs) 1.48
Chandelier Exit (Short, 3 ATRs) 1.72
Upper Bollinger Bands 1.69
Lower Bollinger Band 1.25
Percent B (%b) 0.57
BandWidth 29.77
MACD Line 0.01
MACD Signal Line 0.01
MACD Histogram 0.0039
Fundamentals Value
Market Cap 49.85 Million
Num Shares 33.2 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -2.46
Price-to-Sales 0.00
Price-to-Book 14.11
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.55
Resistance 3 (R3) 1.55 1.53 1.54
Resistance 2 (R2) 1.53 1.51 1.53 1.54
Resistance 1 (R1) 1.51 1.51 1.52 1.52 1.54
Pivot Point 1.49 1.49 1.50 1.49 1.49
Support 1 (S1) 1.48 1.48 1.49 1.48 1.46
Support 2 (S2) 1.46 1.47 1.46 1.46
Support 3 (S3) 1.44 1.46 1.46
Support 4 (S4) 1.45